Senti Biosciences Sets 1-for-33 Reverse Stock Split, Effective Nov. 18

Split-adjusted trading on Nasdaq is expected to begin Nov. 19 under the existing SNTI ticker, with a new CUSIP number.

Two male Asian and Arab researcher scientists working in laboratory, conducting study biohazard substance with scientific equ
Photo: Blue Titan/Shutterstock.com

Key terms

  • Ratio: 1-for-33, effective 5:00 p.m. ET on Nov. 18, 2026
  • Split-adjusted trading expected to begin Nov. 19, 2026 under SNTI
  • New CUSIP 816944201; fractional shares rounded up to a whole share
  • Stockholders approved a 1-for-20 to 1-for-50 range on Oct. 8 and Oct. 15

Senti Biosciences Holdings, Inc. (Nasdaq: SNTI) has effected a 1-for-33 reverse stock split of its common stock, effective 5:00 p.m. Eastern Time on Nov. 18, 2026, the company said in an 8-K filed that day.

Trading on The Nasdaq Capital Market is expected to begin on a split-adjusted basis when the market opens on Nov. 19, 2026, under the existing ticker SNTI. The new CUSIP number is 816944201.

What changes for holders

Every 33 shares of common stock issued or outstanding were automatically reclassified into one new share, without any action required from holders, the filing says. Proportionate adjustments will be made to exercise prices and to the number of shares underlying outstanding equity awards and certain agreements. The split did not change the number of authorized shares or the $0.0001 par value.

No fractional shares will be issued. Holders who would otherwise receive a fractional share will have it rounded up to the nearest whole share. The filing does not describe a cash payment in lieu of fractional shares.

Stockholder approval

Stockholders approved the split at the 2026 Annual Meeting, held Oct. 8 and reconvened Oct. 15, 2026. The approval allowed a ratio of any whole number from 1-for-20 to 1-for-50, at the board's discretion. The board approved the 1-for-33 ratio on Oct. 26.

The filing does not state the company's reason for the split. It also does not give the number of shares outstanding before or after the split.

Sources

Written with AI from the company's SEC filing and our market data, and checked against those sources before publishing. Our editorial standards.

SNTI page →

Filings, figures and price history are on the Senti Biosciences page.